Platelet transfusion refractory patients Book Section
| Authors: | Budhai, A.; Gupta, G. K. |
| Editors: | Shaz, B. H.; Hillyer, C. D.; Schwartz. J.; Reyes Gil, M. |
| Article/Chapter Title: | Platelet transfusion refractory patients |
| Abstract: | Platelet refractoriness, which may be due to immune or nonimmune causes, can be a serious issue in patients requiring platelet transfusion support. Nonimmune-mediated causes include medications, hepatomegaly, splenomegaly, graft-versus-host disease, and infection. Approximately, 30%-40% of cases of platelet refractoriness are immune mediated, with antibodies against class I human leukocyte antigens being largely responsible for these cases. However, the presence of class I human leukocyte antigen alloantibodies does not necessarily implicate these antibodies as the cause of refractoriness. Management of patients with platelet refractoriness includes the provision of fresher ABO-matched platelets, HLA-matched platelets based on recipient HLA-A and HLA-B antigens, platelets that are crossmatch compatible, or platelets lacking the HLA-A or HLA-B antigens that a patient is known to be alloimmunized against. A multidisciplinary approach, involving the clinical team, the transfusion service, and the blood supplier, is necessary for optimal care of platelet refractory patients. © 2025 Elsevier Inc. All rights reserved. |
| Keywords: | transfusion; platelets; hla antibodies; refractoriness; corrected count increment |
| Book Title: | Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. 4th ed |
| ISBN: | 978-0-323-96014-4 |
| Publisher: | Elsevier Inc. |
| Publication Place: | Amsterdam, Netherlands |
| Date Published: | 2025-01-01 |
| Start Page: | 313 |
| End Page: | 315 |
| Language: | English |
| DOI: | 10.1016/b978-0-323-96014-4.00035-5 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book chapter: 66 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work